The Investigation of the Therapeutic Effect of Adropin on Gentamicin-Induced Experimental Nephropathy

OBJECTIVE: In this study, we aimed to evaluate the therapeutic effect of adropin on gentamicin nephrotoxicity.

MATERIAL and METHODS: Rats were divided into 4 groups: 1) Control group: It was allowed to nutrition orally. Did not any injection. 2) Adropin group (5 pmol/kg/day): Rats received daily (5 pmol/kg/day) dose of adropin intraperitoneal injections were performed. 3) Gentamicin group (100 mg/kg/day): Rats received daily (100 mg/kg/day) dose of gentamicin intraperitoneal injections were performed. 4) Adropin+Gentamicin group (5 pmol/kg/day adropin+100 mg/kg/day gentamicin): Rats received daily (5 pmol/kg/day) dose of adropin and (100 mg/kg/day) dose of gentamicin were performed simultaneously. At the end of the study, blood samples for biochemical tests, renal tissue samples for immuno-histochemical and tunnel tests, were taken. Serum and tissue adropin levels are examined with elisa. The prevalence of immunoreactivity in staining (0.1: <25%, 0.4: 26-50, 0.6: 51-75, 0.9: 76- 100) and severity (0: none, +0.5: 2: moderate, +3: severe) Histoscore = prevalence x severity. Harris hematoxylin stain was used for the evaluation of TUNEL staining. Blue stained nuclei were normal, and brown stained cells were apoptotic. At least 500 cells were counted as normal and apoptotic in the 10x growth areas at randomly selected areas. Apoptotic index (AI) was calculated by the ratio of apoptotic cells to total (normal + apoptotic) cells

RESULTS: It was revealed with ELISA and immunohistochemically that the adropin levels of the kidney tissue was decreased in the gentamicin group. A decrease was detected on TUNNEL positivity in the adropin group when compared with the gentamicin group.

CONCLUSION: In conclusion, our data revealed that the adropin levels decrease in renal failure and exogenous adropin could potentially have a protective effect against renal injury.